Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Comparison of Caco-2 and MDCK Cells As an In-Vitro ADME Screening Model

In-Vitro 흡수특성 검색모델로서 Caco-2 및 MDCK 세포배양계의 특성 비교 평가

  • Go, Woon-Jung (BK21 Project team, College of Pharmacy, Chosun University) ;
  • Cheon, Eun-Pa (BK21 Project team, College of Pharmacy, Chosun University) ;
  • Han, Hyo-Kyung (BK21 Project team, College of Pharmacy, Chosun University)
  • Published : 2008.06.20
Download PDF
⟨ Previous Next ⟩

Abstract

The present study compared the feasibility of Caco-2 and MDCK cells as an efficient in-vitro model for the drug classification based on Biopharmaceutics Classification System (BCS) as well as an in-vitro model for drug interactions mediated by P-gp inhibition or P-gp induction. Thirteen model drugs were selected to cover BCS Class I{\sim}IV$ and their membrane permeability values were evaluated in both Caco-2 and MDCK cells. P-gp inhibition studies were conducted by using vinblastine and verapamil in MDCK cells. P-gp induction studies were also performed in MDCK cells using rifampin and the P-gp expression level was determined by western blot analysis. Compared to Caco-2 cells, MDCK cells required shorter period of time to culture cells before running the transport study. Both Caco-2 and MDCK cells exhibited the same rank order relationship between in-vitro permeability values and human permeability values of all tested model compounds, implying that those in-vitro models may be useful in the prediction of human permeability (rank order) of new chemical entities at the early drug discovery stage. However, in the case of BCS drug classification, Caco-2 cells appeared to be more suitable than MDCK cells. P-gp induction by rifampin was negligible in MDCK-cells while MDCK cells appeared to be feasible for P-gp inhibition studies. Taken all together, the present study suggests that Caco-2 cells might be more applicable to the BCS drug classification than MDCK-cells, although MDCK cells may provide some advantage in terms of capacity and speed in early ADME screening process.

Keywords

References

  1. Shah P, Jogani V, Bagchi T and Misra A, Role of Caco-2 cell monolayers in prediction of intestinal drug absorption, Biotechnol. Prog., 22, 186-98 (2006) https://doi.org/10.1021/bp050208u
  2. Tang F, Horie K and Borchardt RT, Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?, Pharm. Res., 19, 765-72 (2002) https://doi.org/10.1023/A:1016140429238
  3. G.L. Amidon, H. Lennernas, V.P. Shah and J.R. Crison, A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm. Res., 12, 413-420 (1995) https://doi.org/10.1023/A:1016212804288
  4. R. L. Juliano and V. Ling., A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants, Biochem. Biophys. Acta., 455, 152-162 (1976) https://doi.org/10.1016/0005-2736(76)90160-7
  5. A. H. Schinkel, C. A. Mol, E. Wagenaar, L. van Deemter, J. J. Smit and P. Borst. Multidrug resistance and the role of Pglycoprotein knockout mice, Eur. J. Cancer, 31A, 1295-1298 (1995)
  6. C-Y. Wu and L.Z. Benet, Predicting drug disposition via application of BCS Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system, Pharm. Res., 22, 11-23 (2005) https://doi.org/10.1007/s11095-004-9004-4
  7. R. Huang, D.J. Murry, D. Kolwankar, S.D. Hall and D.R. Foster, Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines, Biochem. Pharmacol., 71, 695-1704 (2006)
  8. A. Geick, M. Eichelbaum and O. Burk, Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin, J. Biol. Chem., 276, 14581-7 (2001) https://doi.org/10.1074/jbc.M010173200
  9. Lobenberg R and Amidon GL., Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards, Eur. J. Pharm. Biopharm., 50, 3-12 (2000) https://doi.org/10.1016/S0939-6411(00)00091-6
  10. Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki H and Tokuda H, Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells, Eur. J. Pharm. Sci., 10, 195-204 (2000) https://doi.org/10.1016/S0928-0987(00)00076-2
  11. Volpe DA., Variability in Caco-2 and MDCK cell-based intestinal permeability assays, J. Pharm. Sci., 97, 712-25, (2008) https://doi.org/10.1002/jps.21010
  12. Takamatsu N, Kim ON, Welage LS, Idkaidek NM, Hayashi Y, Barnett J, Yamamoto R, Lipka E, Lennernäs H, Hussain A, Lesko L and Amidon GL., Human jejunal permeability of two polar drugs: cimetidine and ranitidine, Pharm. Res., 18, 742-4 (2001) https://doi.org/10.1023/A:1011020025338
  13. Winiwarter S, Bonham NM, Ax F, Hallberg A, Lennernäs H and Karlen A., Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach, J. Med. Chem., 41, 4939-49 (1998) https://doi.org/10.1021/jm9810102
  14. Takamatsu N, Welage LS, Idkaidek NM, Liu DY, Lee PI, Hayashi Y, Rhie JK, Lennernas H, Barnett JL, Shah VP, Lesko L and Amidon GL, Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion, Pharm. Res., 14, 1127-32 (1997) https://doi.org/10.1023/A:1012134219095